Our Portfolio

AgeneBio Inc

Michela Gallagher, PhD | Maryland, United States

Project Overview

  • Biotechnology/For Profit Organization Type
  • $150,000 Funding Amount
  • 9/1/18 — 12/31/20 Project Duration
  • Clinical Program
  • Synaptic Activity and Neurotransmitters Target
  • Clinical Phase 3 Therapeutic Stage
  • Closed Status

AgeneBio Inc

Michela Gallagher, PhD | Maryland, United States

2018 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Imaging Sub-study for the HOPE4MCI Phase 3 Trial

GET IN TOUCH